Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
Eli Lilly (NYSE: LLY) and Incyte (NASDAQ: INCY) are marching forward in their quest to gain regulatory approval for Olumiant as a treatment for atopic dermatitis (AD), commonly referred to as eczema. https://www.globenewswire.com/news-release/2020/02/11/1983486/0/en/Lilly and-Incyte-Announce-Positive-Top-Line-Results-from-the-North-American-Phase-3-Study-BREEZE-AD5-of-Oral-Selective-JAK-Inhibitor-Baricitinib-in-Patients-with-Moderate-to-Severe.html
Last month, the companies showed that the drug in combination with topical corticosteroids helped patients reduce their eczema symptoms. And now the healthcare companies have demonstrated that the monotherapy is able to help eczema patients as well.
Image source: Getty Images.
Source Fool.com
